License and Collaboration Agreement - Lilly License and Collaboration Agreement (Details) $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
	Apr. 02, 2018 USD ($) item	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
License and Collaboration Agreement
Collaboration revenue		$ 2,883	$ 2,704	$ 6,048	$ 5,662
Current liabilities		33,320		33,320		$ 34,888
Lilly License and Collaboration Agreement
License and Collaboration Agreement
Amount of research and development costs the Company is responsible to cover	$ 47,500
Threshold amount of research and development costs above which the collaboration partner is responsible for	$ 47,500	47,500
Minimum number of members from the Company and partner on joint research committee | item	3
Non-refundable, non-creditable upfront payment received	$ 62,500
Sales based milestone payments receivable	$ 250,000
Term of the license and collaboration agreement	10 years
Upfront payment	$ 62,500
Allocation of transaction price to combined performance obligation	56,600			5,500
Allocation of transaction price to Phase I supply	5,900			600
Increase in total estimated costs expected to be incurred				6,100
Collaboration revenue		2,900	2,600	6,000	5,500
Current liabilities		16,300		16,300		17,000
Contract with customer liability, deferred revenue		$ 16,323	$ 26,229	$ 16,323	$ 26,229	$ 22,367	$ 19,206	$ 28,859	$ 31,777
Research and development services performance obligation period				2 years		2 years
Lilly License and Collaboration Agreement | First Licensed Product
License and Collaboration Agreement
Maximum payments to be received from collaboration partner if milestones are met	165,000
Lilly License and Collaboration Agreement | Additional Licensed Product
License and Collaboration Agreement
Maximum payments to be received from collaboration partner if milestones are met	$ 160,000